Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- The University of Hong Kong
- Enrollment
- 194
- Locations
- 5
- Primary Endpoint
- Recurrence of endometrioma
Study Overview
Brief Summary
Endometriosis is a chronic inflammatory disease that affects approximately 10-15% of women of reproductive age. Symptoms include dysmenorrhoea, chronic pelvic pain, dyspareunia and infertility. Removal of the endometriotic cyst (chocolate cyst) by surgery is a well-established treatment for symptomatic relief. However, recurrence of endometriotic cyst after surgical removal of the cyst is up to 30-50% after ovarian surgery. Oral contraceptive pills for 18-24 months after the surgery is widely used as a postoperative hormonal therapy because it has been shown to reduce the chance of recurrence of the endometriotic cyst, but recurrence is still high even after taking oral contraceptive pills.
Letrozole is an aromatase inhibitor. There are some preliminary reports that letrozole can cause shrinkage of endometriotic cysts and improve endometriosis-related pelvic pain by reducing oestrogen level, inflammation and stem cell recruitment that may be important in recurrence of endometriotic cyst. This is a randomized double-blinded placebo-controlled trial. The aim of this study is to assess whether taking letrozole in addition to oral contraceptive pills in the first 6 months after laparoscopic surgery (key-hole surgery) to remove the endometriotic cyst can reduce the risk of recurrence compared to oral contraceptive pills alone. The study also involves laboratory parts from a small portion of the endometriotic cyst specimens (removed during laparoscopy ovarian cystectomy) and endometrial biopsy (if the patient agrees) to assess the role of stem cells in the pathogenesis of endometriotic cysts.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Women aged 18-45 years old
- •Scheduled to have laparoscopic ovarian cystectomy
- •Unilateral or bilateral endometrioma on pre-operative ultrasound and confirmed by histology
Exclusion Criteria
- •Use of long-acting hormonal therapy in the 3 months before inclusion in the study
- •Histological report of laparoscopic ovarian cystectomy showed atypical endometrioma
- •Complex surgery including resection of deep infiltrating disease, bowel resection or hysterectomy
- •Incomplete excision of endometrioma/ incision or drainage rather than ovarian cystectomy
- •Suspicion of malignancy
- •Contraindications to combined oral contraceptive pills, including: uncontrolled hypertension (systolic > 160mmHg or diastolic > 100mmHg), diabetes with retinopathy/ nephropathy/ neuropathy, current or past history of venous thromboembolism, ischemic heart disease, history of cerebrovascular accident, migraine with aura, severe liver disease, oestrogen-sensitive cancers, undiagnosed abnormal uterine bleeding, smokers (> 15 cigarettes/day) aged 35 years or above, or having body mass index >=35 kg/m2
- •Planning to get pregnant in the coming 1 year
- •Refusal to join the study
Arms & Interventions
Letrozole
They will be given letrozole 2.5mg daily on top of combined oral contraceptive (COC) pills (Microgynon 30, which contains 30mcg ethinyloestradiol and 150 mcg levonorgestrel) orally for 6 months after laparoscopic ovarian cystectomy, followed by COC pills alone subsequently as routine
Intervention: Letrozole (Drug)
Standard treatment
They will be given placebo tablets (which will be identical to letrozole) on top of COC pills (Microgynon 30, which contains 30mcg ethinyloestradiol and 150 mcg levonorgestrel) orally for 6 months after laparoscopic ovarian cystectomy, followed by COC pills alone subsequently
Intervention: Placebo (Other)
Outcomes
Primary Outcomes
Recurrence of endometrioma
Time Frame: 12 months
the presence of ovarian cysts with the typical sonographic criteria of endometriomas and a diameter of ≥30 mm after previous complete ovarian cystectomy, to be measured by a transvaginal or transrectal ultrasound transducer
Secondary Outcomes
- Use of additional analgesics(6 months, 12 months, 24 months)
- Endometriosis Health Profile Questionnaire (EHP-30) score(6 months, 12 months, 24 months)
- Non-menstrual pelvic pain (chronic pelvic pain, deep dyspareunia) and dysmenorrhoea measured by a 10cm visual analogue pain scale (VAS)(6 months, 12 months, 24 months)
- Menstrual regularity(6 months, 12 months, 24 months)
- Side effects/ adverse events(6 months, 12 months, 24 months)
- Need for further surgery for endometriosis(6 months, 12 months, 24 months)